Summary
5-MAPDB is a dihydrobenzofuran entactogen first characterized by Monte et al. (1993) and pharmacologically profiled by Rickli et al. (2015). It acts as a relatively selective serotonin releaser (SERT IC50 โ1.2 ฮผM) with minimal dopamine transporter activity (DAT IC50 โ77 ฮผM), giving it a highly serotonergic profile more selective than MDMA. Human experience reports are limited and contradictory, with some users describing subdued, sedating effects and others reporting MDMA-like empathy and euphoria.
Dose Information
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | 50-75mg | 75-120mg | 120-150mg | 150mg+ |
Light
Common
Strong
Heavy
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | After Effects | Total |
|---|---|---|---|---|---|---|
| Oral | 45-70 min | 30-60 min | 2-4 hrs | 1-2 hrs | 2-4 hrs | 300-0 min |
| Insufflated | 5-15 min | 15-30 min | 2-4 hrs | 1-2 hrs | 2-4 hrs | 300-0 min |
| Rectal | 5-15 min | 15-30 min | 2-4 hrs | 1-2 hrs | 2-4 hrs | 300-0 min |
Tolerance
Build-up
develops rapidly after a single use
Reset
7โ14 days for baseline
Effects
Positive
- Stimulation
- Increased energy/alertness
Negative
- Pupil dilation
- Bruxism
- Jaw clenching
- Sweating
- Insomnia during comedown
- Weight loss
- Difficulty urinating
- Reduced appetite
- Decreased need for sleep
- Decreased appetite
- Distrubed sleep patterns
- Bruxia
Positive
- Euphoria
- Empathy
- Emotional openness
- Increased sociability
- Enhanced music appreciation
- Mood lift
Negative
- Next-day lethargy or low mood
- Agressiveness
- Excessive talking
- Moodiness
Positive
- Enhanced tactile sensation
- Mild visual enhancement
- Tactile enhancement
- Increased music appreciation
- Bodily control enhancement
- Increased libido
- Tracers
Negative
- Light sensitivity
- Increase sexuality
- Visual and audiotory hallucinations itchiness